ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0082

Comparative Immunology of Entheseal Anchorage Sites Between Spine, Hip and Knee Demonstrates up to 70-fold Greater IL-23 Induction from Axial Enthesis Bone: A New Angle on the Failure of IL-23 Blockade in Ankylosing Spondylitis

Mark Harland1, Paula David2, Chi Wong1, Jake Weddell1, Abhay Rao3, Almas Khan3, Jake Timothy3, Peter Loughenbury3, Robert Dunsmuir3, Vishal Borse3, Campbell MacEachern3, Antonius Pieter Van der Heuvel4, Warner Chen4, Tom Macleod1 and Dennis McGonagle5, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK, Leeds, United Kingdom, 2Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel, Ramat Gan, Israel, 3Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, 4Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, USA, Spring House, PA, 5National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, cytokines, immunology, Spondyloarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SpA Including PsA – Basic Science Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Both peripheral and axial spondyloarthropathy (SpA), psoriasis and inflammatory bowel disease are strongly linked to IL-23 pathway immunogenetics and immunology. Unexpectedly, IL-23 inhibition lacked efficacy in axial disease, namely Ankylosing Spondylitis (AS). Myeloid cells, which are substantial producers of IL-23, are rich in the red spinal marrow so we hypothesised considerable differences may exist between axial and peripheral sites, where haematopoiesis is less active.  Therefore, we performed comparative immune studies of spinal, hip, and knee enthesis peri-entheseal bone (PEB) for IL-23 induction following stimulation.

Methods: Spinous process (n=5), hip capsule (n=4), and knee (n=4) PEB collected during orthopaedic surgery was mechanically digested to extract entheseal immune cells. Cell subsets were phenotyped by flow cytometry and stimulated with LPS and zymosan to assess IL-23-producing capacity. Quantification of cytokine production was achieved by ELISA and LEGENDplex assays.

Results: Despite similar cell populations present across each site, myeloid cells including monocytes and neutrophils were numerically more abundant per gram of tissue in the red marrow of spine and hip PEB but scarce in peripheral yellow marrow PEB, in keeping with the fact the spine and hip are haematopoietically active whereas the knee in adults is not. Following stimulation, spine and hip PEB produced 25-70 fold more IL-23 than knee PEB per gram of tissue (spine = 659.5 pg/g, hip = 1382.1 pg/g, knee = 24.8 pg/g; Figure 1).

Conclusion: his comparative immunology study of adult human entheses demonstrates axial PEB, the key target of AS pathology, produces significantly more IL-23 than knee PEB.   The findings from our ex vivo stimulation studies raise the possibility that high-dosing regimens of IL-23 blockers may be needed to treat Ankylosing Spondylitis.

Supporting image 1

Figure 1: Red marrow PEB has logarithmically more cells and produces more IL_23 per gram of tissue than peripheral yellow marrow PEB. A) Population numbers of cell subsets isolated from red marrow PEB (spine and hip) and peripheral PEB (knee) determined by flow cytometry. B) IL_23 produced by entheseal cells isolated from spine, hip, and knee PEB following 24hr stimulation with LPS (10 ng/ml) + interferon gamma (20ng/ml) or zymosan (10 µg/ml) + interferon gamma (20 ng/ml).


Disclosures: M. Harland: None; P. David: None; C. Wong: None; J. Weddell: None; A. Rao: None; A. Khan: None; J. Timothy: None; P. Loughenbury: None; R. Dunsmuir: None; V. Borse: None; C. MacEachern: None; A. Van der Heuvel: None; W. Chen: None; T. Macleod: None; D. McGonagle: AbbVie, 2, 5, 6, Celgene, 2, 5, 6, Janssen, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 6.

To cite this abstract in AMA style:

Harland M, David P, Wong C, Weddell J, Rao A, Khan A, Timothy J, Loughenbury P, Dunsmuir R, Borse V, MacEachern C, Van der Heuvel A, Chen W, Macleod T, McGonagle D. Comparative Immunology of Entheseal Anchorage Sites Between Spine, Hip and Knee Demonstrates up to 70-fold Greater IL-23 Induction from Axial Enthesis Bone: A New Angle on the Failure of IL-23 Blockade in Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/comparative-immunology-of-entheseal-anchorage-sites-between-spine-hip-and-knee-demonstrates-up-to-70-fold-greater-il-23-induction-from-axial-enthesis-bone-a-new-angle-on-the-failure-of-il-23-blockad/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-immunology-of-entheseal-anchorage-sites-between-spine-hip-and-knee-demonstrates-up-to-70-fold-greater-il-23-induction-from-axial-enthesis-bone-a-new-angle-on-the-failure-of-il-23-blockad/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology